Other substances

KBP-COVID-19

COVID-19 candidate vaccine

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
1
 Clinical trials

General information

The candidate vaccine being developed by Kentucky Bioprocessing is an RBD-based type of candidate vaccine. It is based on the protein subunit platform. Currently, this COVID-19 candidate vaccine is being evaluated in a Phase I/II clinical trial. 

 

Supporting references

Link Tested on Impact factor Notes Publication date
Draft landscape of COVID-19 candidate vaccines
healthy adults Jul/28/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04473690 KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers Active, not recruiting Phase 1|Phase 2 Dec/30/2020 Dec/31/2022
  • Alternative id - KBP-201
  • Interventions - Biological: Low Dose of KBP-COVID-19|Biological: High Dose of KBP-COVID-19|Biological: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Palm Beach Research Center, West Palm Beach, Florida, United States|Velocity Clinical Research, Meridian, Idaho, United States|PMG Research of Winston-Salem, Winston-Salem, North Carolina, United States|PanAmerican Clinical Research, Brownsville, Texas, United States|ICON, San Antonio, Texas, United States|DM Clinical Research, Tomball, Texas, United States|LMC Manna Research, Burlington, Burlington/Ontario, Canada|LMC Manna Research, Montréal, Point Claire, Quebec, Canada
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 101
  • Age - 18 Years to 85 Years   (Adult, Older Adult)
  • Outcome measures - Solicited Administration site reactions|Solicited systemic events|Unsolicited Adverse Events and medically attended adverse events|Serious Adverse Events, Medically Attended Adverse Events and New Onset Chronic Diseae|Vaccine ELISA and neutralizing antibody titers for each treatment group|Seroconversion rates
Export (.csv)